Patent US2831198A successfully refreshed from Google Patents.
Patent US4649132A successfully refreshed from Google Patents.
US4649132A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of Factor VIII inhibitors
Assignee: Scripps Research Institute
•
Filing: 1985-05-24
•
Granted: 1987-03-10
•
Expires: 2005-05-24
Abstract
Abstract Fragments of human Factor VIII:C which bind to antibody inhibitors of Factor VIII in patients afflicted with such inhibitors are disclosed. The method of treating Factor VIII inhibitors, by administering one or more of these fragments, is also disclosed.
Inventors
- 👤 Theodore S. Zimmerman
- 👤 Carol A. Fulcher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 21:58
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/36; C07K14/00; C07K14/435; C07K14/745; C07K14/755; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/86; A; A61; A61K; A61K38/00; G01N2333/00; G01N2333/435; G01N2333/745; G01N2333/755; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/10
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
145 words
A polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII selected from the group consisting of: (i) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 394-465; (ii) fragments whose amino-terminal residue is one of residues 395-466 and whose carboxyl-terminal residue is one of residues 472-492; (iii) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 472-492; (iv) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1708-1775; (v) fragments whose amino-terminal residue is one of residues 1709-1776 and whose carboxyl-terminal residue is one of residues 1782-1802; and (vi) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1782-1802.
Claim 2
Dependent Claim
145 words
A polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII selected from the group consisting of: (i) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 394-465; (ii) fragments whose amino-terminal residue is one of residues 395-466 and whose carboxyl-terminal residue is one of residues 472-492; (iii) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 472-492; (iv) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1708-1775; (v) fragments whose amino-terminal residue is one of residues 1709-1776 and whose carboxyl-terminal residue is one of residues 1782-1802; and (vi) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1782-1802.
Claim 3
Dependent Claim
61 words
A polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII selected from the group consisting of (i) amino acid residues 380-394; (ii) amino acid residues 466-472; (iii) amino acid residues 380-472; (iv) amino acid residues 1694-1708; (v) amino acid residues 1776-1782; and (vi) amino acid residues 1694-1782.
Claim 4
Dependent Claim
61 words
A polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII selected from the group consisting of (i) amino acid residues 380-394; (ii) amino acid residues 466-472; (iii) amino acid residues 380-472; (iv) amino acid residues 1694-1708; (v) amino acid residues 1776-1782; and (vi) amino acid residues 1694-1782.
Claim 5
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 380-394.
Claim 6
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 466-472.
Claim 7
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 380-472.
Claim 8
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 1694-1708.
Claim 9
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 1776-1782.
Claim 10
Dependent Claim
25 words
A polypeptide according to claim 2 whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 1694-1782.
Claim 11
Dependent Claim
37 words
A Factor VIII inhibitor neutralizing polypeptide whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 1690-2332, and which is essentially free of other fragments of human Factor VIII.
Claim 12
Dependent Claim
37 words
A Factor VIII inhibitor neutralizing polypeptide whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 1690-2332, and which is essentially free of other fragments of human Factor VIII.
Claim 13
Dependent Claim
37 words
A Factor VIII inhibitor neutralizing polypeptide whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 373-740, and which is essentially free of other fragments of human Factor VIII.
Claim 14
Dependent Claim
37 words
A Factor VIII inhibitor neutralizing polypeptide whose amino acid sequence is that of the fragment of human Factor VIII composed of amino acid residues 373-740, and which is essentially free of other fragments of human Factor VIII.
Claim 15
Dependent Claim
41 words
A Factor VIII inhibitor neutralizing product comprising polypeptides whose amino acid sequences are those of the fragments of human Factor VIII composed of amino acid residues 1690-2332 and 373-740, and which is essentially free of other fragments of human Factor VIII.
Claim 16
Dependent Claim
41 words
A Factor VIII inhibitor neutralizing product comprising polypeptides whose amino acid sequences are those of the fragments of human Factor VIII composed of amino acid residues 1690-2332 and 373-740, and which is essentially free of other fragments of human Factor VIII.
Claim 17
Dependent Claim
35 words
A therapeutic composition comprising an amount of one or more polypeptides according to claim 1 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
35 words
A therapeutic composition comprising an amount of one or more polypeptides according to claim 2 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 19
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 3 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
34 words
A therapeutic composition comprising an amount of a polypeptide according to of claim 4 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 5 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 6 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 23
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 7 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 24
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 8 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 25
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 9 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
33 words
A therapeutic composition comprising an amount of a polypeptide according to claim 10 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 27
Dependent Claim
33 words
A therapeutic composition comprising an amount of a product according to claim 11 effective to neutralize Factor VIII inhibitor activity in a patient exhibiting such activity, in association with a pharmaceutically acceptable carrier.
Claim 28
Dependent Claim
30 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of one or more polypeptides according to claim 1.
Claim 29
Dependent Claim
29 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount one or more polypeptides according to claim 2.
Claim 30
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 3.
Claim 31
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 4.
Claim 32
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 5.
Claim 33
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 6.
Claim 34
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 7.
Claim 35
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 8.
Claim 36
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 9.
Claim 37
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a polypeptide according to claim 10.
Claim 38
Dependent Claim
28 words
A method of alleviating Factor VIII inhibitory activity in a patient suffering therefrom, comprising administering to such patient an effective amount of a product according to claim 11.
References Cited (Backward Citations)
US4361509A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-03-09 | 1990-09-08 | 1991-03-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-03-09 | 1994-09-08 | 1995-03-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-03-09 | 1998-09-08 | 1999-03-10 | $7700.00 | Window Closed / Lapsed |